RiaSTAP (CSL Behring GmbH)


Welcome to the PulseAid listing for the RiaSTAP drug offered from CSL Behring GmbH. This Human Blood Coagulation Factor [EPC],Increased Coagulation Activity [PE],Blood Coagulation Factors [Chemical/Ingredient] pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view the details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.

LABELER NAME / MANUFACTURER: CSL Behring GmbH
NON-PROPRIETARY NAME: FIBRINOGEN HUMAN
SUBSTANCE NAME: FIBRINOGEN HUMAN
TYPE: PLASMA DERIVATIVE
PHARMA CLASS: Human Blood Coagulation Factor [EPC],Increased Coagulation Activity [PE],Blood Coagulation Factors [Chemical/Ingredient]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2009-01-16
END MARKETING DATE: 0000-00-00


RiaSTAP PLASMA DERIVATIVE Details:

Item DescriptionRiaSTAP from CSL Behring GmbH
LABELER NAME: CSL Behring GmbH
DEA SCHEDULE:
ACTIVE STRENGTH: 1300(mg/50mL)
START MARKETING DATE: 2009-01-16
END MARKETING DATE: 0000-00-00
PRODUCT ID: 63833-891_b9fd1cc1-5a93-4161-8b06-d0476209de6f
PRODUCT NDC: 63833-891
APPLICATION NUMBER: BLA125317

Other FIBRINOGEN HUMAN Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
CSL Behring GmbHRiaSTAP